OncoGenex Pharmaceuticals, Inc. (OGXI) Posts Q4 Loss of 98c/Share
Get Alerts OGXI Hot Sheet
Join SI Premium – FREE
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) reported Q4 EPS of ($0.98), $0.37 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $1.86 million.
For earnings history and earnings-related data on OncoGenex Pharmaceuticals, Inc. (OGXI) click here.
For earnings history and earnings-related data on OncoGenex Pharmaceuticals, Inc. (OGXI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Motus GI Holdings (MOTS) Tops Q4 EPS by 130c
- Tango Therapeutics, Inc. (TNGX) Misses Q4 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!